Multivesicular Liposome (Depofoam) in Human Diseases

AuthorBahare Salehien
AuthorAbhay P. Mishraen
AuthorManisha Nigamen
AuthorFarzad Kobarfarden
AuthorZeeshan Javeden
AuthorSadegh Rajabien
AuthorKhushbukhat Khanen
AuthorHafiz Ahsan Ashfaqen
AuthorToqeer Ahmaden
AuthorRaffaele Pezzani en
AuthorKarina Ramírez-Alarcónen
AuthorMiquel Martorellen
AuthorWilliam C. Choen
AuthorSeyed Abdulmajid Ayatollahien
AuthorJavad Sharifi-Raden
Issued Date2020-04-30en
AbstractDrug development is a key point in the research of new therapeutic treatments for increasing maximum drug loading and prolonged drug effect. Encapsulation of drugs into multivesicular liposomes (DepoFoam) is a nanotechnology that allow delivery of the active constituent at a sufficient concentration during the entire treatment period. This guarantees the reduction of drug administration frequency, a very important factor in a prolonged treatment. Currently, diverse DepoFoam drugs are approved for clinical use against neurological diseases and for post-surgical pain management while other are under development for reducing surgical bleeding and for post-surgical analgesia. Also, on pre-clinical trials on cancer DepoFoam can improve bioavailability and stability of the drug molecules minimizing side effects by site-specific targeted delivery. In the current work, available literature on structure, preparation and pharmacokinetics of DepoFoam are reviewed. Moreover, we investigated approved DepoFoam formulations and preclinical studies with this nanotechnology.en
DOIhttps://doi.org/10.22037/ijpr.2020.112291.13663en
URIhttps://brieflands.com/journals/ijpr/articles/124653en
KeywordDepoFoamen
KeywordDepocyten
KeywordEncapsulationen
KeywordNanotechnologyen
KeywordDrugsen
PublisherBrieflandsen
TitleMultivesicular Liposome (Depofoam) in Human Diseasesen
TypeReview Article_importeden

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
ijpr-19-9.pdf
Size:
363.15 KB
Format:
Adobe Portable Document Format
Description:
Article/s PDF